SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193805-21-001525
Filing Date
2021-11-03
Accepted
2021-11-03 16:01:32
Documents
14
Period of Report
2021-11-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 e621052_8k-summit.htm   iXBRL 8-K 24965
2 e621052_ex99-1.htm EX-99.1 12359
6 GRAPHIC logo.jpg GRAPHIC 7112
  Complete submission text file 0001193805-21-001525.txt   227665

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA smmt-20211103.xsd EX-101.SCH 3034
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE smmt-20211103_lab.xml EX-101.LAB 34916
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE smmt-20211103_pre.xml EX-101.PRE 22795
7 EXTRACTED XBRL INSTANCE DOCUMENT e621052_8k-summit_htm.xml XML 3658
Mailing Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 211375238
SIC: 2834 Pharmaceutical Preparations